pseudoephedrine Side Effects
Also known as: Sudafed
Analysis of 9,450 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
9,450
Death-Related
3,156
33.4% of reports
Hospitalizations
3,766
39.9% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 3,156 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| SYSTEMIC LUPUS ERYTHEMATOSUS | 1,408 |
| TYPE 2 DIABETES MELLITUS | 1,404 |
| WOUND | 1,385 |
| SYNOVITIS | 1,371 |
| RHEUMATOID ARTHRITIS | 1,367 |
| OFF LABEL USE | 1,353 |
| RASH | 1,338 |
| PSORIATIC ARTHROPATHY | 1,333 |
| SWELLING | 1,283 |
| PERICARDITIS | 1,275 |
| INFUSION RELATED REACTION | 1,272 |
| PEMPHIGUS | 1,271 |
| GLOSSODYNIA | 1,260 |
| JOINT SWELLING | 1,253 |
| HAND DEFORMITY | 1,251 |
| PAIN | 1,230 |
| DUODENAL ULCER PERFORATION | 1,195 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1,189 |
| FIBROMYALGIA | 1,171 |
| ABDOMINAL DISCOMFORT | 1,160 |
Reactions in Hospitalization Reports
Top reactions in 3,766 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| RHEUMATOID ARTHRITIS | 1,895 |
| SYSTEMIC LUPUS ERYTHEMATOSUS | 1,868 |
| SYNOVITIS | 1,813 |
| OFF LABEL USE | 1,785 |
| SWELLING | 1,773 |
| RASH | 1,748 |
| PEMPHIGUS | 1,727 |
| PAIN | 1,725 |
| PERICARDITIS | 1,725 |
| ABDOMINAL DISCOMFORT | 1,722 |
| WOUND | 1,694 |
| INFUSION RELATED REACTION | 1,657 |
| GLOSSODYNIA | 1,646 |
| JOINT SWELLING | 1,642 |
| ALOPECIA | 1,637 |
| FATIGUE | 1,636 |
| HAND DEFORMITY | 1,631 |
| HEPATIC ENZYME INCREASED | 1,608 |
| DRUG INEFFECTIVE | 1,569 |
| DUODENAL ULCER PERFORATION | 1,554 |
Nearby — Related Medications
What the FAERS Data Reveals About pseudoephedrine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 9,450 voluntary reports linked to pseudoephedrine and its brand equivalents (Sudafed), spanning 2004 through 2025. Of those, 3,156 (33.4%) listed death as an outcome and 3,766 (39.9%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 92% were female and 8% male; age distribution skews toward 18-44, with 3,647 reports in that bracket. The single most reported reaction is systemic lupus erythematosus with 5,062 submissions, followed by pain and drug ineffective.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.